Search
Close this search box.
Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS) Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia Leading Research. Delivering Hope.Open Medicine Foundation® Canada

Time is running out! Make a difference before 2023 ends!

Time is running out! Make a difference before 2023 ends! Your donation to Open Medicine Foundation can help accelerate groundbreaking clinical trials for ME/CFS and Long COVID. Together, we can discover effective treatments faster. Act now to be a part of this vital mission. Your gift gets us further, faster.

As the year closes, we remind you that your gift impacts the lives of real people – giving hope, and inspiring change. Today we share Agy’s story, a powerful testament to the resilience of the human spirit and the critical need for research in the fight against ME/CFS
and Long COVID.

 

Since 2015, Agy has battled with symptoms that defied explanation, pushing through with determination until ME/CFS made it impossible to ignore. The path to diagnosis was fraught with challenges, from being dismissed as simply depressed to undergoing costly and ineffective treatments.

 

Picture of Agy with a note that says: "Missing from weight lifting, cycling, climbing, trekking, socializing, having friends, walking. Missed out on a career in biomedical science. Missing from life since 2017."Before her diagnosis, Agy’s life was characterized by her passion for fitness and her career as a gym manager and personal trainer. She enjoyed climbing, trekking, and riding her motorbike — a life full of activity and achievement.

 

Today, Agy’s reality is drastically different. Housebound and often confined to laying down for 22 hours a day, the disease has stripped away the joys that once fueled her vitality. Despite the daily struggle, she endures with the hope that research will soon find effective treatments.

 

On Agy’s toughest days, hope is kindled by the dedication of OMFCA’s research team working tirelessly to understand ME/CFS. 

 

Agy shares, “OMFCA has some of the world’s greatest scientists working on ME/CFS, many of whom have family members or friends with the disease. This means, unlike much of science, they are not looking for glory, to be the first to publish findings which can slow down the process considerably. They are working collaboratively, sharing research as it happens, on the fastest way to treatments, which is the number one objective.”

 

At OMFCA, we are doing just that. We are working urgently to pave the fastest path possible to effective treatments. 

 

This year, OMFCA funded more research and more education for healthcare providers than ever before. We even launched OMFCA’s StudyME Participant Registry to help connect research with those willing to be studied –7,000 people signed-up already! You made history with us through your support of OMF in the past and we are so grateful.

 

Last year, we promised you OMFCA would pursue clinical treatment trials. We are now in the final stages of launching OMFCA’s first treatment  trial. You, and the OMFCA community, made it happen. 

 

The Life Improvement Trial will be a randomized, double-blind placebo, four-part Mestinon/LDN trial looking at the effectiveness of these drugs to reduce brain fog, fatigue, post-exertional malaise and postural orthostatic tachycardia syndrome (POTS). This trial will also provide critical information about  ME/CFS based on analyzing participant blood samples. Finally, The LIFT will establish the infrastructure for future clinical treatment trials funded by OMFCA.

 

The pain and desperation these diseases cause must end now. Will you help OMFCA push research further and faster? Thank you for your support in 2023 and beyond. Thank you for your support in 2023 and beyond. In case you missed it, check out the amazing milestones you made possible in 2023. Your donation will help continue to push forward in 2024. 

 

An infographic chart shows OMF's 2023 milestones, including 36 active research projects, clinical trials, and the launch of OMF's StudyME Registry.